Mitch Sayare, PhD, was the co-founder, Chairman, and CEO of NASDAQ-listed ImmunoGen, Inc. (IMGN), a billion-dollar biotechnology company focused on the development of anti-cancer drugs. Its first FDA-approved product, Kadcyla, is sold worldwide by Roche Pharma for the treatment of Her2-positive breast cancer.
Dr. Sayare began his professional career as an Assistant Professor of Biochemistry and Biophysics at the University of Connecticut. Dr. Sayare serves on the boards of several for-profit companies, including NASDAQ-listed Altimmune, of which he is also chairman; Advanced Aesthetic Technologies; and Energies. He is chairman of the board of The Lundquist Institute in Los Angeles, a member of the Dean’s Council of the WP Carey School of Business at Arizona State University and is co-founder of the ASU Health Futures Council.
